1. Ackermann D, Biedermann C, Bailly G, Studer U (1986) Behandlung oberflächlicher Blasentumoren mit rIFN-aA-Instillation (Roferon A): eine Phase I und II Studie. In: Ackermann R (Hrsg) Verhandlungsbericht der Deutschen Gesellschaft für Urologie, Springer, Berlin, p 211–212
2. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnern EM, Spiegel RJ, Zighelboim J (1985) Intraperitoneal recombinant a-interferon for „salvage“ immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 45: 4447–4453
3. Borden EC, Yamamoto N, Hogan TF, Edwards BS, Bryan GT (1981) In: Münk K, Kirchner H (Hrsg) Interferon. Properties, mode of action, production, clinical applica-tion. S. Karger, Basel, pp 42–52
4. Borden EC, Edwards BS, Hawkins MJ, Merritt JA, Sielaff KM, Groveman DS, Za- remba KS, Schiller J, Willson JVK (1985) Design considerations for phase II trials of interferons in bladder, breast, and colorectal carcinomas. In: Zoon K (Hrsg) Interferon: Research, clinical application, and regulatory consideration. Elsevier, North Holland, pp 207–217
5. Brouty-Boye D, Mogensen KE, Gresser I (1985) Effects of long-term treatment of human carcinoma cells with interferon a. Eur J Cancer Clin Oncol 21: 507–514